Home> Products> type 2 diabetes mellitus

{ "products": [ { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35e1c4d6823e26538d21d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (12.5mg), Metformin Hydrochloride (500mg)", "description": "GLIEMPAFLOZIN MET 12.5mg/500mg is a powerful combination medication formulated to manage type 2 diabetes mellitus (T2DM) effectively. It contains Empagliflozin (12.5mg) and Metformin Hydrochloride (500mg), two potent anti-diabetic agents that work synergistically to regulate blood sugar levels. This medication helps in improving glycemic control while reducing the risk of diabetes-related complications. It is prescribed as an adjunct to diet and exercise to enhance blood glucose regulation in adults with type 2 diabetes.\n\n \nKey Benefits:\n \n\n Effective Blood Sugar Control: Helps in lowering HbA1c levels, leading to better long-term glucose management.\nPromotes Weight Loss: Empagliflozin assists in weight reduction by eliminating excess glucose through urination.\nReduces Cardiovascular Risk: Beneficial for patients with heart-related complications linked to diabetes.\nImproves Insulin Sensitivity: Metformin enhances insulin action, reducing insulin resistance.\nPrevents Kidney Damage: Helps in reducing the burden on kidneys by decreasing glucose reabsorption.\nConvenient Combination Therapy: Eliminates the need for multiple medications by combining two effective drugs in one tablet.\n \nHow Does It Work?\n \n\nGLIEMPAFLOZIN MET 12.5mg/500mg works through a dual mechanism:\n\nEmpagliflozin blocks SGLT2 in the kidneys, preventing glucose reabsorption and promoting its excretion through urine. This leads to a significant reduction in blood sugar levels.\n\nMetformin lowers hepatic glucose production, decreases intestinal glucose absorption, and enhances insulin sensitivity, ensuring better blood glucose utilization by the body.\n\n \nDirections for Use:\n \n\nTake one tablet daily or as directed by your healthcare provider.\n\nSwallow the tablet whole with a glass of water. Do not crush or chew it.\n\nIt is recommended to take the medication with food to minimize gastrointestinal side effects.\n\nFollow a balanced diet and regular exercise regimen for optimal results.\n\nMonitor blood sugar levels regularly to ensure proper dosage adjustments.\n\n \nSide Effects:\n \n\nAlthough GLIEMPAFLOZIN MET 12.5mg/500mg is well tolerated, some patients may experience mild to moderate side effects, including:\n\nFrequent Urination due to glucose excretion\n\nDehydration or thirst\n\nHypoglycemia (Low Blood Sugar) when used with other anti-diabetic medications\n\nGastrointestinal Issues such as nausea, diarrhea, or stomach discomfort\n\nUrinary Tract Infections (UTIs) due to increased glucose in urine\n\nLactic Acidosis (Rare but Serious) in some cases due to Metformin", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "tablet daily", "balanced diet", "medication helps", "nausea diarrhea", "experience mild", "body directions", "significant reduction", "effective drugs", "multiple medications", "weight reduction", "work synergistically", "empagliflozin 125mg", "cases due", "diabetesrelated complications", "increased glucose", "glucose excretion dehydration", "regular exercise regimen", "metformin hydrochloride 500mg", "frequent urination due", "heartrelated complications linked", "blood glucose utilization", "eliminating excess glucose", "moderate side effects", "gliempaflozin met 125mg500mg", "healthcare provider swallow", "improving glycemic control", "potent antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2050, "imageuri": "https://productimages.withfloats.com/actual/67a35e57b167fbeb7927d316.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35e57b167fbeb7927d316.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:48:28.684Z", "updatedon": "2025-03-17T11:04:23.276Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-12-5mg-metformin-hydrochloride-500mg-/2050", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET 12.5mg/ 500mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 12.5 mg+metformin 500 mg", "empagliflozin/metformin 5 mg/1000 mg", "Empagliflozin 12.5 mg brands in India", "empagliflozin 12.5 mg+metformin 500 mg price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35d815432f8f0afe662b4", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "empagliflozin 25mg+ metformin hydrochloride (extended release) 1000 mg", "description": "GLIEMPAFLOZIN MET ER is a combination medication used to manage type 2 diabetes mellitus (T2DM) by helping control blood sugar levels effectively. It contains two powerful anti-diabetic agents, Empagliflozin and Metformin Hydrochloride (Extended Release), which work together to enhance glucose regulation and reduce the risk of diabetes-related complications. This medication is recommended for patients who require additional glycemic control beyond lifestyle changes and monotherapy treatments.\n\n \nKey Benefits\n \n\n Effective Blood Sugar Control – Helps reduce and maintain optimal blood glucose levels in type 2 diabetic patients.\nWeight Management – Empagliflozin promotes caloric loss through urinary glucose excretion, potentially aiding in weight reduction.\nReduced Risk of Cardiovascular Diseases – Beneficial for heart health, lowering the risk of cardiac complications in diabetic patients.\nInsulin Sensitivity Improvement – Metformin enhances insulin function, reducing insulin resistance.\nLower Risk of Hypoglycemia – A balanced mechanism of action ensures stable blood glucose levels without sudden drops.\nKidney Protection – Empagliflozin may help protect against diabetic nephropathy by reducing kidney stress.\nExtended-Release Formula – Ensures long-lasting blood sugar control with a once-daily dosage for improved patient compliance.\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor) – Blocks the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion through urine, thereby reducing blood sugar levels.\nMetformin Hydrochloride (Biguanide) – Reduces glucose production in the liver, enhances insulin response, and delays glucose absorption in the digestive tract.\nTogether, they provide a dual action approach for better glycemic control while minimizing side effects like hypoglycemia.\n \nDirections for Use\n \n\nDosage: Take one tablet per day, preferably with food or as directed by your healthcare provider.\nSwallow whole with a glass of water; do not crush or chew.\n Maintain a healthy diet and follow a regular exercise routine for optimal results.\nRegular monitoring of blood sugar levels is advised.\nDo not stop taking this medication without consulting your doctor.\n\n \nSide Effects:\n \n\nSome individuals may experience mild to moderate side effects, including:\n\nFrequent urination (due to glucose excretion)\nDehydration (increased fluid loss)\nNausea, vomiting, or stomach upset\nDiarrhea or constipation\nMetallic taste in the mouth\nLow blood pressure (Hypotension)\nVitamin B12 deficiency (with long-term use of Metformin)\nUrinary tract infections (UTIs) or genital infections\n Seek medical attention if you experience severe allergic reactions, extreme dizziness, or difficulty breathing.", "price": 245.0, "discountamount": 74.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "combination medication", "hypoglycemia directions", "oncedaily dosage", "difficulty breathing", "experience mild", "stop taking", "healthy diet", "chew maintain", "day preferably", "glycemic control", "digestive tract", "sglt2 protein", "diabetic nephropathy", "balanced mechanism", "cardiac complications", "diabetesrelated complications", "constipation metallic taste", "stomach upset diarrhea", "frequent urination due", "moderate side effects", "doctor side effects", "blood sugar levels", "regular exercise routine", "healthcare provider swallow", "minimizing side effects", "dual action approach", "delays glucose absorption", "improved patient compliance", "heart health lowering", "cardiovascular diseases beneficial", "enhance glucose regulation" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2049, "imageuri": "https://productimages.withfloats.com/actual/67a35d9d1b599c6f20ba1fa7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35d9d1b599c6f20ba1fa7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:45:53.712Z", "updatedon": "2025-03-27T09:45:21.627Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-metformin-hydrochloride-extended-release-1000-mg/2049", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET ER ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin + metformin brand name in india", "empagliflozin + metformin combination brand name", "empagliflozin 12.5 mg+metformin 500 mg price", "Empagliflozin and metformin hydrochloride extended-release tablets", "Empagliflozin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35c945c5e728a14d08ad8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (25mg), Linagliptin (5mg)", "description": "GLIEMPAFLOZIN LINA 25mg/5mg is a combination medication designed for individuals managing type 2 diabetes mellitus. It contains Empagliflozin (25mg) and Linagliptin (5mg), two potent anti-diabetic agents that work together to control blood sugar levels effectively. This medication is typically prescribed to patients who require dual therapy to achieve optimal glycemic control when diet and exercise alone are insufficient.\n\n \nKey Benefits :\n \n\nEffective Blood Sugar Control: Regulates blood glucose levels efficiently in patients with type 2 diabetes.\n\nWeight Management: Empagliflozin promotes weight loss by removing excess glucose from the body.\n\nHeart and Kidney Benefits: Shown to provide cardiovascular and renal protection, reducing the risk of heart failure.\n\nLower Risk of Hypoglycemia: Minimal chances of low blood sugar episodes compared to other anti-diabetic medications.\n\nConvenient Dual Therapy: Combines two complementary mechanisms for enhanced glycemic control in a single tablet.\n\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor): This component blocks Sodium-Glucose Cotransporter-2 (SGLT2) in the kidneys, preventing glucose reabsorption and facilitating its elimination through urine. This leads to a significant reduction in blood sugar levels.\n\nLinagliptin (DPP-4 Inhibitor): It inhibits Dipeptidyl Peptidase-4 (DPP-4) enzyme, which increases incretin hormone levels. This enhances insulin secretion and suppresses glucagon production, leading to better post-meal glucose control.\n\n \nDirections for Use\n \n\nTake one tablet daily, preferably at the same time each day.\n\nSwallow the tablet whole with water, with or without food.\n\nFollow the dosage regimen prescribed by your healthcare provider.\n\nRegular monitoring of blood sugar levels is recommended.\n\n \nSide Effects\n \n\nAlthough GLIEMPAFLOZIN LINA 25mg/5mg is generally well-tolerated, some patients may experience:\n\nFrequent Urination: Due to glucose excretion through urine.\n\nDehydration or Thirst: Increased urination may lead to mild dehydration.\n\nUrinary Tract Infections (UTIs): A common side effect associated with SGLT2 inhibitors.\n\nNasal Congestion or Sore Throat: Occasionally observed with DPP-4 inhibitors.\n\nGastrointestinal Discomfort: Mild nausea or diarrhea in some cases.\n\nHypotension (Low Blood Pressure): Especially in patients with pre-existing conditions.\n\n ", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "urine dehydration", "preexisting conditions", "generally welltolerated", "food follow", "day swallow", "significant reduction", "single tablet", "complementary mechanisms", "provide cardiovascular", "body heart", "linagliptin 5mg", "empagliflozin 25mg", "glucose excretion", "typically prescribed", "tablet daily preferably", "combination medication designed", "dosage regimen prescribed", "removing excess glucose", "common side effect", "thirst increased urination", "gliempaflozin lina 25mg5mg", "recommended side effects", "blood sugar levels", "enhances insulin secretion", "enhanced glycemic control", "hypoglycemia minimal chances", "renal protection reducing", "kidney benefits shown", "require dual therapy", "potent antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2048, "imageuri": "https://productimages.withfloats.com/actual/67a35cb9b07d7c125c0f536d.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35cb9b07d7c125c0f536d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:41:56.39Z", "updatedon": "2025-03-17T11:04:56.55Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-linagliptin-5mg-/2048", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN LINA 25mg/ 5mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin-linagliptin 25-5 mg price", "Empagliflozin and Linagliptin brands in India", "empagliflozin-linagliptin 10-5 mg", "Fixed dose combination of Empagliflozin and Linagliptin Tablets Price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c935a743fd2358222332", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.2 ", "description": "VOGLIGOLD 0.2 \nVoglibose (0.2mg)\nIntroduction to VOGLIGOLD 0.2\nVOGLIGOLD 0.2 is a medication designed to manage type 2 diabetes mellitus by helping to control blood sugar levels. It contains Voglibose, an alpha-glucosidase inhibitor, which works by slowing down the digestion and absorption of carbohydrates from the intestines. This action helps to prevent spikes in blood sugar levels after meals. VOGLIGOLD 0.2 is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVoglibose 0.2mg\nVoglibose is a potent alpha-glucosidase inhibitor. It works by inhibiting the alpha-glucosidase enzyme in the small intestine, which is responsible for breaking down complex carbohydrates into simple sugars. By inhibiting this enzyme, Voglibose slows down the conversion of carbohydrates into glucose, thereby reducing the postprandial (after-meal) rise in blood sugar levels.\n\nSlows Carbohydrate Absorption: By delaying the absorption of glucose, Voglibose helps to smooth out the postprandial blood glucose peaks.\nReduces Postprandial Hyperglycemia: It specifically targets the blood sugar spikes that occur after meals, making it an effective treatment for controlling postprandial hyperglycemia.\nBenefits of VOGLIGOLD 0.2\nEffective Postprandial Blood Sugar Control\nManages After-Meal Blood Sugar Levels: VOGLIGOLD 0.2 helps to manage and reduce the rise in blood sugar levels that occur after meals.\nComplementary Therapy: It can be used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to provide comprehensive glycemic control.\nAdditional Health Benefits\nWeight Neutral: Voglibose is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Voglibose has a low risk of causing hypoglycemia (low blood sugar), as it does not increase insulin secretion directly.\nHow to Use VOGLIGOLD 0.2\nDosage and Administration\nRecommended Dosage: The typical dosage of VOGLIGOLD 0.2 is one tablet taken three times a day, just before meals.\nAdministration: Take the tablet whole with a glass of water, just before starting your meal. This timing ensures that the medication works effectively by inhibiting the enzyme responsible for carbohydrate digestion.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD 0.2 regularly at the same times each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-0-2-133456", "price": 89.0, "discountamount": 26.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "rise", "diet", "Order", "EMAIL", "meals", "glass", "water", "option", "action", "adults", "timing", "patients", "Low Risk", "exercise", "readings", "metformin", "VOGLIGOLD", "Voglibose", "Mechanism", "Guidelines", "intestines", "same times", "one tablet", "conversion", "Optimal Use", "weight gain", "conjunction", "Adjustments", "combination", "information", "Introduction", "Hypoglycemia", "sterisonline", "sterispharma", "best results", "simple sugars", "CALL/WHATSAPP", "Key Component", "sulfonylureas", "Weight Neutral", "typical dosage", "treatment plan", "Administration", "Consistent Use", "small intestine", "low blood sugar", "insulin secretion", "blood sugar spikes", "Recommended Dosage", "Regular monitoring", "healthcare provider", "effective treatment", "complex carbohydrates", "Complementary Therapy", "carbohydrate digestion", "Meal Blood Sugar Levels", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "type 2 diabetes mellitus", "Postprandial Hyperglycemia", "Additional Health Benefits", "other diabetes medications", "comprehensive glycemic control", "other antidiabetic medications", "postprandial blood glucose peaks", "potent alpha-glucosidase inhibitor", "Effective Postprandial Blood Sugar Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1515, "imageuri": "https://productimages.withfloats.com/actual/667d34025e58b0758f70570b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d34025e58b0758f70570b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:47:49.18Z", "updatedon": "2024-06-27T09:42:22.871Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-0-2-/1515", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD 0.2 ", "category": "DIABETIC RANGE", "tags": [ "voglibose side effects", "voglibose 0.2 mg side effects", "voglibose 0.2mg dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661ad3166170d1ff8cb4574", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nTENELIGOLD PIO 20/15 is a combination medication that contains Teneligliptin and Pioglitazone. It is primarily used in the management of type 2 diabetes mellitus, a condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nTeneligliptin: Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the DPP-4 enzyme, which in turn enhances the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones stimulate insulin secretion and inhibit glucagon release, leading to improved glucose control after meals.\n\nPioglitazone: Pioglitazone belongs to the thiazolidinedione class of medications. It works by improving insulin sensitivity in muscle and adipose (fat) tissues, reducing glucose production in the liver, and enhancing glucose uptake in peripheral tissues. This helps lower blood sugar levels and improves overall glycemic control.\n\nBenefits of TENELIGOLD PIO 20/15:\nComprehensive Glycemic Control: The combination of Teneligliptin and Pioglitazone addresses different aspects of glucose metabolism, providing comprehensive control over fasting and postprandial (after-meal) blood sugar levels.\n\nEnhanced Insulin Sensitivity: Pioglitazone improves insulin sensitivity in cells, allowing better utilization of glucose and reducing insulin resistance.\n\nIncretin Hormone Enhancement: Teneligliptin enhances the action of incretin hormones, which regulate insulin secretion and glucagon levels, leading to better glucose regulation after meals.\n\nCardioprotective Effects: Pioglitazone has been associated with cardiovascular benefits such as improved lipid profiles and reduced risk of cardiovascular events in some patients.\n\nHow to Use TENELIGOLD PIO 20/15:\nDosage: The typical dosage is one tablet taken orally once daily, usually with meals. Your healthcare provider will determine the appropriate dosage based on your medical condition and response to treatment.\n\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your doctor.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-pio-20-15-134077", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "risk", "turn", "Order", "EMAIL", "GLP-1", "water", "glass", "meals", "cells", "liver", "action", "muscle", "doctor", "adipose", "fasting", "patients", "response", "treatment", "one tablet", "management", "information", "medications", "utilization", "Pioglitazone", "postprandial", "fat) tissues", "DPP-4 enzyme", "sterispharma", "sterisonline", "CALL/WHATSAPP", "Teneligliptin", "teneligold-pio", "glucose uptake", "lipid profiles", "typical dosage", "Administration", "TENELIGOLD PIO", "glucagon levels", "glucose control", "glucagon release", "DPP-4) inhibitor", "incretin hormones", "medical condition", "different aspects", "insulin secretion", "glucose production", "insulin resistance", "appropriate dosage", "glucose metabolism", "glucose regulation", "peripheral tissues", "healthcare provider", "cardiovascular events", "comprehensive control", "combination medication", "dipeptidyl peptidase-4", "thiazolidinedione class", "cardiovascular benefits", "high blood sugar levels", "Cardioprotective Effects", "overall glycemic control", "type 2 diabetes mellitus", "meal) blood sugar levels", "Enhanced Insulin Sensitivity", "Incretin Hormone Enhancement", "inadequate insulin production", "Comprehensive Glycemic Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1480, "imageuri": "https://productimages.withfloats.com/actual/6661ad34c749b7962dbc4345.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661ad34c749b7962dbc4345.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:36:01.592Z", "updatedon": "2024-06-28T12:39:29.014Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1480", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD PIO 20/15", "Teneligliptin", "Pioglitazone", "Teneligliptin uses", "Teneligliptin side effects", "Teneligliptin 20mg", "Teneligliptin+Metformin", "Teneligliptin 20 mg price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661a4c8870e7b20c49e5b6e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD 20 ", "description": "TENELIGOLD 20 \nTeneligliptin (20mg)\nIntroduction to TENELIGOLD 20\nTENELIGOLD 20 contains Teneligliptin 20mg, a medication primarily used for the management of type 2 diabetes mellitus. Teneligliptin belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which help control blood sugar levels by enhancing the body's own ability to regulate insulin after meals. This medication is typically used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nWhat is Teneligliptin?\nOverview of Teneligliptin\nTeneligliptin is an oral diabetes medication that helps increase insulin production and decrease glucose production in the liver. It works by inhibiting the DPP-4 enzyme, which results in prolonged activity of incretin hormones. These hormones play a significant role in regulating glucose metabolism.\n\nMechanism of Action\nIncretin Hormones: Teneligliptin enhances the levels of incretin hormones, which increase insulin synthesis and release from pancreatic beta cells in response to meals.\nGlucose Regulation: It reduces the liver’s production of glucose, especially after meals, thereby helping to lower blood sugar levels.\nReduced Blood Sugar Spikes: By increasing insulin release and decreasing glucagon levels, Teneligliptin helps control blood sugar spikes after meals.\nBenefits of TENELIGOLD 20\nEffective Blood Sugar Management\nPostprandial Glucose Control: TENELIGOLD 20 helps manage postprandial (after-meal) blood sugar levels by enhancing the body’s natural response to meals.\nFasting Blood Sugar Control: It also helps in lowering fasting blood sugar levels, providing a balanced glycemic control throughout the day.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: TENELIGOLD 20 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nCombination Therapy: It can be used alone or in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin for enhanced glycemic control.\nAdditional Health Benefits\nWeight Neutral: Teneligliptin is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Teneligliptin has a low risk of causing hypoglycemia compared to some other diabetes medications.\nHow to Use TENELIGOLD 20\nDosage and Administration\nRecommended Dosage: The typical dosage of TENELIGOLD 20 is one tablet taken once daily. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet with or without food. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take TENELIGOLD 20 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-20-133447", "price": 165.0, "discountamount": 49.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "diet", "food", "body", "water", "drugs", "class", "EMAIL", "meals", "Order", "liver", "adults", "Action", "option", "ability", "Support", "Overview", "Low Risk", "readings", "patients", "metformin", "Mechanism", "same time", "TENELIGOLD", "full glass", "one tablet", "Guidelines", "information", "weight gain", "Optimal Use", "Adjustments", "Hypoglycemia", "sterispharma", "Introduction", "sterisonline", "best results", "DPP-4 enzyme", "sulfonylureas", "CALL/WHATSAPP", "Administration", "treatment plan", "typical dosage", "Consistent Use", "Weight Neutral", "glucagon levels", "insulin release", "natural response", "Exercise Adjunct", "significant role", "excellent adjunct", "insulin synthesis", "incretin hormones", "Recommended Dosage", "insulin production", "glucose production", "Glucose Regulation", "glucose metabolism", "prolonged activity", "Teneligliptin 20mg", "Combination Therapy", "individual response", "healthcare provider", "Diabetes Management", "Blood Sugar Control", "pancreatic beta cells", "lifestyle modifications", "meal) blood sugar levels", "type 2 diabetes mellitus", "oral diabetes medication", "enhanced glycemic control", "balanced glycemic control", "Additional Health Benefits", "Reduced Blood Sugar Spikes", "other diabetes medications", "Postprandial Glucose Control", "other antidiabetic medications", "Effective Blood Sugar Management", "dipeptidyl peptidase-4 (DPP-4) inhibitors" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1471, "imageuri": "https://productimages.withfloats.com/actual/6661a4ca0c19ea48b9490a9f.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661a4ca0c19ea48b9490a9f.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:00:08.3Z", "updatedon": "2024-06-29T05:31:45.493Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-20-/1471", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD 20 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD 20", "Teneligliptin (20mg)", "Teneligliptin Tablets 20 mg uses", "Teneligliptin 20 mg price", "Teneligliptin 20 mg side effects", "Teneligliptin 20 mg uses in Hindi", "Teneligliptin+Metformin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }